SUMMARY In this double-blind crossover trial, naproxen (750 mg/day) was compared to placebo for the treatment of osteoarthrosis of the hip and knee. Patients were randomly assigned to treatment with either naproxen or placebo for 4 weeks and then to treatment with the alternate agent for a second 4-week period. 8 out of 9 objective and subjective measurements of drug efficacy clearly differentiated naproxen from placebo at highly significant levels (P=00001 to 0 0004). Patient daily check lists of osteoarthrotic symptoms also showed a statistically significant difference between naproxen and placebo therapy. Both physicians and patients, when asked to give a 'final drug preference', showed a significant preference for naproxen over placebo. In general, the incidence of side effects was low and approximately the same for both naproxen and placebo. Laboratory assessments showed little difference between groups. The trial showed naproxen to be an effective and well tolerated drug for the treatment of osteoarthrosis of the hip and knee.
Osteoarthrosis is a very common disorder characterised by cartilaginous degeneration, osteophytosis, and deformity of the joint margins. Weight-bearing joints are frequently affected. Studies have shown that by the age of 40, 90% of all persons have degenerative changes in the weight-bearing joints (Lowman, 1955) .
Aspirin has been the cornerstone of drug therapy for osteoarthrosis. However, because of its known side effects, research has been directed toward the development of new nonsteroidal anti-inflammatory agents with low toxicity. Naproxen (Naprosyn) is one of these newer agents. Clinical studies have shown it to be an effective, well tolerated drug for the treatment of rheumatoid arthritis (Helby-Peterson et al., 1973; Hill et al., 1974; Bowers et al., 1975; Huskisson et al., 1976 ). In addition, earlier studies have suggested that naproxen is also effective for the relief of the signs and symptoms of osteoarthrosis (Cochrane, 1973; Kageyama, 1973; Tanaka et al., 1976) . Accordingly, this study was designed to further evaluate the efficacy and tolerance of napAccepted for publication July 5, 1977 Correspondence to Dr Carter Multz, Syntex Corporation, 3401 Hillview Avenue, Palo Alto, California 94304, USA roxen for the treatment of osteoarthrosis of the two commonly affected weight-bearing joints, the hip and knee.
Methods

SELECTION OF PATIENTS
Patients who had actively symptomatic osteoarthrosis of the hip and knee were selected using three admission criteria: (1) At the final double-blind examination the physician and then the patient independently indicated whether one phase of the crossover was much better, better, or no different than the other for the relief of symptoms. The physician then also evaluated the overall side effects for each phase of the crossover (none, mild, moderate, or severe). In addition, patients were requested to complete a daily checklist t2-tailed probability using Wilcoxon-Mann-Whitney test (Koch, 1972 *Out of a total of 79 patients evaluated; includes all available data. 6 patients failed to complete the checklist. t2-tailed probability using Wilcoxon-Mann-Whitney test (Koch, 1972) .
grading 6 disease-related variables (e.g. duration of morning stiffness).
SAFETY EVALUATION
At the beginning of the trial and every 4 weeks during the trial, the following laboratory investigations were performed: complete blood count, routine urinalysis, alkaline phosphatase, total cholesterol, total bilirubin, total protein, albumin level, SGOT, LDH, serum creatinine, blood glucose, blood urea nitrogen, serum uric acid, calcium, phosphorus, sodium, potassium, and chloride. At each visit stools were tested for occult blood using the Hemoccult slide method. At each examination the patients were asked if they had experienced any symptoms which they thought might be caused by the medication.
Results
RESPONSE TO DRUG THERAPY
Analysis of the variables studied showed naproxen to be effective in relieving the symptoms of osteoarthrosis. 8 out of the 9 objective and subjective measurements of drug efficacy given in Table 1 clearly differentiated naproxen from placebo at highly significant levels (P=0 0001 to 0-004). Pain on motion or tenderness was reduced, activities of daily living were easier, the overall severity of symptoms was less, the duration of morning stiffness was reduced, and walking time improved. Range of motion was also significantly improved for affected knees. Swelling, while sometimes present in the affected knee joints, was generally absent or mild and thus presented limited potential for statistical discrimination. Although the naproxen-placebo difference for this variable failed to reach statistical significance, the difference favoured naproxen.
The patient daily checklists also helped to evaluate drug efficacy. As Table 2 shows, the findings closely paralleled those in Table 1 . All variables showed a statistically significant difference between naproxen and placebo therapy. Naproxen reduced the patients' pain with activity, nocturnal pain, morning stiffness, and functional impairment as judged by the patients' ability to get in and out of a car, walk one block, or tie shoelaces.
Of the 79 patients who participated in both phases of the trial, 77 completed the naproxen phase, and 42 completed the placebo phase. 2 did not complete the naproxen phase because of inadequate disease control. 37 failed to complete the placebo phase of the study: 35 because of inadequate disease control and 2 because of side effects. The difference between the number who prematurely discontinued placebo (37) and the number who discontinued naproxen (2) was statistically significant (P=0-0001).
Finally, the two drugs were evaluated using the physicians' and patients' assessment of 'final drug preferences'. Subjective forms of assessment such as this have been found to be sensitive indicators of drug efficacy (Lee et al., 1973 (Lee et al., , 1976 . While still under double-blind conditions, the investigator considered the naproxen period better or much better in 58 instances, the placebo period better or much better in 12 instances, the two drugs equal in nine instances. This difference was statistically significant (P<0-00001). The patients' own preferences closely paralleled those of the physician (Fig.) .
SIDE EFFECTS
Two of the 89 patients who were originally admitted to the study withdrew in the first phase of the trial due to mild gastrointestinal side effects (nausea and dyspepsia) while on naproxen. Neither was included in the efficacy evaluations. One of these patients Four of the original 89 patients admitted to the study withdrew or terminated one phase of the crossover prematurely because of suspected side effects while receiving placebo. One patient (with pre-existing macular degeneration) withdrew because of blurred vision, a second because ofabdominal pain and difficulty in concentrating. Neither was included in the efficacy analysis.
An additional 2 patients complained of abdominal pain, nausea, vomiting, and/or dyspepsia during placebo administration. Both patients were prematurely crossed over to the second phase of the trial and completed 4 weeks of naproxen therapy without developing side effects. Since data from both phases of the trial were available for these 2 patients, they were among the 79 patients included in the efficacy analysis. In general, the incidence of side effects was low and approximately the same for both naproxen and placebo ( No major abnormalities due to drug therapy were seen. Although there were occasional deviations from the normal range, the mean laboratory values for all patients were normal throughout the trial.
Discussion
Osteoarthrosis is the most common form of joint disease seen by the practising physician. As yet, however, control of its pathogenesis is beyond the grasp of current understanding, the treatment therefore remains symptomatic rather than specific. The actual choice of treatment depends on the extent of discomfort or disability. Mild symptoms can often be adequately treated with reassurance, rest, and physical therapy. On the other hand, more severe symptoms require drug therapy. Active treatment is essential not only for the immediate benefits of increased comfort and function, but for retarding disease progression and protecting contralateral joints which may be exposed to increased stress (Moskowitz, 1972a) .
While osteoarthrosis is primarily a degenerative process, inflammatory changes have been noted in some patients (Crain, 1961; Ehrlich, 1975; Kellgren and Moore, 1952) . Inflammatory synovitis is frequently found both clinically and at surgery, and while this synovitis is less severe than that seen in rheumatoid arthritis it may still contribute significantly to the patient's symptoms. Whatever the cause of this inflammation, anti-inflammatory analgesic drugs are often more beneficial than simple analgesics alone.
Aspirin has been used as the main drug therapy in osteoarthrosis. However, osteoarthrosis is a disorder of older people whose concomitant illnesses may include marginal cardiovascular and cerebrovascular function with frequent impairment of vision and hearing. As a result, these patients are more likely to develop aspirin toxicity (Moskowitz, 1972b) .
In this study naproxen was found to be an effective and well tolerated drug, supporting the findings of Aagaard (1975) in a previous double-blind crossover study of naproxen (500 mg/day) versus placebo. In that study naproxen was shown to cause statistically significant improvement in pain at rest, walking time, and pain on effort. Side effects were found to be slight and occurred in approximately the same frequency during naproxen and placebo administration.
The results of our study suggest that naproxen is a potentially useful alternative to aspirin for the management of osteoarthrosis. Its 13-hour half-life makes twice-a-day dosage possible, and offers an additional benefit to some patients.
